Central Health

centralhealth.nl.ca

Central Health is the second largest health region in Newfoundland and Labrador, providing health and community services to approximately 20 per cent of the province’s population. Our 94,000 clients, patients, residents, and their families live in 177 communities in a region that extends from Charlottetown in the east, Fogo Island in the north, Harbour Breton in the south, to Baie Verte in the west.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MICREOS HUMAN HEALTH ENROLLES WORLD'S FIRST ENDOLYSIN-DRUG AS A THERAPY FOR ATOPIC DERMATITIS

Micreos | September 22, 2020

news image

Dutch biotech company Micreos Human Health has enrolled the first patients in a Phase I/IIa, randomized, double-blind, placebo-controlled, parallel treated dose-ranging study to assess the safety and efficacy of XZ.700 in patients with mild to moderate atopic dermatitis. The study marks the world's first evaluation of a pharmaceutical endolysin for topical use in humans. Endolysins are highly specific enzymes that cut the bacterial cell wall, rapidly killing only the target bacteria, regardl...

Read More

INDUSTRIAL IMPACT

AMYRIS TO ACQUIRE MENOLABS FOR MENOPAUSE WELLNESS ACCELERATING GROWTH OF CONSUMER BUSINESS

Amyris, Inc. | January 25, 2022

news image

Amyris, Inc. a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ operating platform announces that it has agreed to exclusive terms to acquire the assets of MenoLabs, LLC, a women-founded company to treat menopause symptoms, drive research for women's health and improve society's understanding of menopause. Amyris previously communicated its intention of launching a new consumer...

Read More

MEDICAL

MERIDIAN BIOSCIENCE LAUNCHES LYO-READY™ QPCR INHIBITOR TOLERANT BLOOD-SPECIFIC MASTER MIXES FOR DNA & RNA DIRECT DETECTION

Meridian Bioscience, Inc. | March 31, 2022

news image

Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of two new master mixes that detect DNA and RNA in crude blood samples down to a single copy – enabling the earliest detection of cancer using non-invasive liquid biopsy. These two innovative mixes, Lyo-Ready™ Direct DNA qPCR Blood Mix and Lyo-Ready™ Direct RNA/DNA qPCR Blood Mix, are designed for applications that requir...

Read More

DIAGNOSTICS

CANCER CELL PAPER IDENTIFIES "AVIDITY ENHANCEMENT" AS NEW STRATEGY FOR IMPROVING CAR T THERAPY FOR ACUTE MYELOID LEUKEMIA

LUMICKS | May 26, 2022

news image

LUMICKS, a leading life science tools company that develops instruments for dynamic single-molecule and cell avidity analysis, today announced the publication in Cancer Cell of preclinical research identifying "Avidity Enhancement" as a new strategy to improve therapeutic outcome of Chimeric Antigen Receptor (CAR) T cell immunotherapy in Acute Myeloid Leukemia (AML). AML poses significant clinical challenges due to its resistance to therapies and its bleak prognosi...

Read More
news image

MICREOS HUMAN HEALTH ENROLLES WORLD'S FIRST ENDOLYSIN-DRUG AS A THERAPY FOR ATOPIC DERMATITIS

Micreos | September 22, 2020

Dutch biotech company Micreos Human Health has enrolled the first patients in a Phase I/IIa, randomized, double-blind, placebo-controlled, parallel treated dose-ranging study to assess the safety and efficacy of XZ.700 in patients with mild to moderate atopic dermatitis. The study marks the world's first evaluation of a pharmaceutical endolysin for topical use in humans. Endolysins are highly specific enzymes that cut the bacterial cell wall, rapidly killing only the target bacteria, regardl...

Read More
news image

INDUSTRIAL IMPACT

AMYRIS TO ACQUIRE MENOLABS FOR MENOPAUSE WELLNESS ACCELERATING GROWTH OF CONSUMER BUSINESS

Amyris, Inc. | January 25, 2022

Amyris, Inc. a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ operating platform announces that it has agreed to exclusive terms to acquire the assets of MenoLabs, LLC, a women-founded company to treat menopause symptoms, drive research for women's health and improve society's understanding of menopause. Amyris previously communicated its intention of launching a new consumer...

Read More
news image

MEDICAL

MERIDIAN BIOSCIENCE LAUNCHES LYO-READY™ QPCR INHIBITOR TOLERANT BLOOD-SPECIFIC MASTER MIXES FOR DNA & RNA DIRECT DETECTION

Meridian Bioscience, Inc. | March 31, 2022

Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of two new master mixes that detect DNA and RNA in crude blood samples down to a single copy – enabling the earliest detection of cancer using non-invasive liquid biopsy. These two innovative mixes, Lyo-Ready™ Direct DNA qPCR Blood Mix and Lyo-Ready™ Direct RNA/DNA qPCR Blood Mix, are designed for applications that requir...

Read More
news image

DIAGNOSTICS

CANCER CELL PAPER IDENTIFIES "AVIDITY ENHANCEMENT" AS NEW STRATEGY FOR IMPROVING CAR T THERAPY FOR ACUTE MYELOID LEUKEMIA

LUMICKS | May 26, 2022

LUMICKS, a leading life science tools company that develops instruments for dynamic single-molecule and cell avidity analysis, today announced the publication in Cancer Cell of preclinical research identifying "Avidity Enhancement" as a new strategy to improve therapeutic outcome of Chimeric Antigen Receptor (CAR) T cell immunotherapy in Acute Myeloid Leukemia (AML). AML poses significant clinical challenges due to its resistance to therapies and its bleak prognosi...

Read More